Welcome to our dedicated page for Reata Pharmaceuticals news (Ticker: RETA), a resource for investors and traders seeking the latest updates and insights on Reata Pharmaceuticals stock.
Reata Pharmaceuticals, Inc. (NASDAQ: RETA) is a clinical-stage biopharmaceutical company dedicated to developing groundbreaking therapeutics for patients with serious or life-threatening diseases. By focusing on the intricate molecular pathways that regulate cellular metabolism and inflammation, Reata aims to innovate treatments that address significant medical needs.
Reata's core expertise lies in targeting the transcription factor NRF2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company's two most advanced clinical candidates, bardoxolone methyl and omaveloxolone, are designed to leverage this mechanism to treat a range of conditions.
Bardoxolone methyl is currently being investigated for its potential benefits in treating chronic kidney disease, while omaveloxolone is under development for the treatment of Friedreich's ataxia, a debilitating neuromuscular disorder. These candidates have shown promising results in clinical trials, positioning Reata as a key player in the biopharmaceutical industry.
Reata has forged strong partnerships with leading healthcare organizations to advance its research and development efforts. Financially, the company remains robust, securing funding through strategic collaborations and public offerings. This financial stability allows Reata to continue its pioneering work in the biopharmaceutical sector.
In recent developments, Reata has achieved significant milestones in its clinical trials, receiving positive feedback from regulatory authorities and expanding its research portfolio. These achievements underscore the company's commitment to delivering innovative therapies that can transform patient outcomes.
For investors and stakeholders, Reata represents a dynamic and promising investment opportunity in the biopharmaceutical industry. With a clear focus on addressing unmet medical needs and a strong pipeline of potential therapies, Reata is well-positioned for future growth and success.
Reata Pharmaceuticals (Nasdaq: RETA) has announced a proposed underwritten public offering of 2,000,000 shares of its Class A common stock, with an option for underwriters to buy an additional 300,000 shares. The offering is conducted under an existing shelf registration statement and will be underwritten by Barclays Capital and Goldman Sachs. The proceeds are aimed at advancing clinical programs for Reata’s investigational drugs, bardoxolone and omaveloxolone, which target serious diseases by regulating cellular metabolism and inflammation.
Reata Pharmaceuticals (Nasdaq: RETA) announced that the FDA reviewed results from the Baseline-Controlled Study of omaveloxolone for Friedreich’s ataxia, concluding they do not reinforce the MOXIe study’s findings. The FDA proposed additional analyses but expressed skepticism due to limited patient numbers. Reata plans to submit these analyses and potentially conduct a second pivotal study. Despite showing improvement in motor function in studies, the FDA's feedback is a setback for Reata and its future development efforts.
Reata Pharmaceuticals reported positive Year 2 results from the Phase 3 CARDINAL study of bardoxolone methyl in patients with chronic kidney disease due to Alport syndrome, demonstrating a significant increase in eGFR. The company plans to submit a New Drug Application (NDA) for bardoxolone in Q1 2021. In addition, the Baseline-Controlled Study for omaveloxolone in Friedreich’s Ataxia showed a notable treatment effect, supporting further regulatory submissions. However, Reata experienced a GAAP net loss of $65.5 million for Q3 2020, influenced by decreased collaboration revenue and increased expenses.
Reata Pharmaceuticals announced that the Phase 3 CARDINAL study of bardoxolone methyl met its primary and key secondary endpoints in patients with chronic kidney disease due to Alport syndrome. At Week 100, bardoxolone showed a statistically significant improvement in eGFR of 7.7 mL/min/1.73 m2 compared to placebo (p=0.0005). The treatment, particularly effective in pediatric patients, was well-tolerated. Reata plans to submit a New Drug Application for full approval in 1Q21, aiming to be the first approved therapy for this life-threatening condition affecting up to 60,000 patients in the U.S.
Reata Pharmaceuticals (Nasdaq: RETA) will report its Q3 2020 financial results and development program updates on November 9, 2020, before market opening. A conference call is scheduled for 8:00 a.m. ET, accessible via toll-free and international numbers. The earnings press release will be available prior to the call on the company's website. Reata develops innovative therapies targeting critical molecular pathways for serious diseases, with two leading candidates, bardoxolone methyl and omaveloxolone, currently under investigation.
Reata Pharmaceuticals (Nasdaq: RETA) recently announced the publication of pivotal results from the MOXIe trial in Annals of Neurology, highlighting the efficacy of omaveloxolone in treating Friedreich's ataxia (FA). In this double-blind study, patients receiving 150 mg daily of omaveloxolone showed a statistically significant improvement in mFARS scores (mean improvement of 2.40 points, p=0.014) after 48 weeks, with good tolerability. Currently, omaveloxolone is an investigational drug with orphan drug designation from the FDA for FA, which affects ~5,000 U.S. patients.
Reata Pharmaceuticals announces the presentation of its KIDNEYCODE program, focusing on genetic testing for patients with chronic kidney disease, at the American Society of Nephrology Kidney Week 2020. The e-poster will be available on October 22, 2020, at 10:00 a.m. EDT. Over 1,000 KIDNEYCODE tests have been conducted in the U.S., illustrating the program's significance. Reata, a clinical-stage biopharmaceutical company, is developing therapies targeting cellular metabolism and inflammation, with investigational drugs bardoxolone methyl and omaveloxolone.
Reata Pharmaceuticals (Nasdaq: RETA) will present efficacy and safety results from the pivotal MOXIe Part 2 study of its investigational drug, omaveloxolone, for Friedreich’s ataxia on September 24, 2020. This presentation is part of the Emerging Science series hosted by the American Academy of Neurology. The study, led by Dr. David Lynch, was selected from over 150 abstracts. In addition, Dr. Lynch will also share findings at the FARA 2020 Biomarker & Clinical Endpoint Meeting, scheduled for the same day. The safety and efficacy of omaveloxolone have not yet been established.
Reata Pharmaceuticals (Nasdaq: RETA) reported its Q2 2020 financial results and provided a regulatory update on its drug candidates. The FDA has granted a pre-NDA meeting for Bardoxolone in Alport Syndrome, aiming for NDA submission by Q4 2020. For Omaveloxolone, a required second pivotal trial was suggested by the FDA. The company recorded a GAAP net loss of $67.6 million, compared to $34.4 million in Q2 2019. Reata secured a $350 million investment from Blackstone Life Sciences, bolstering its cash reserves of $610.4 million as of June 30, 2020. The cash is expected to fund operations through 2023.
Reata Pharmaceuticals (Nasdaq: RETA) will release its financial results for Q2 2020 and provide updates on its development programs on August 10, 2020, before market hours. A conference call will follow at 8:30 a.m. ET, accessible via phone or webcast. Reata specializes in novel therapeutics targeting serious diseases, with key candidates bardoxolone methyl and omaveloxolone focusing on inflammation and mitochondrial function. These drugs are still in development, and their safety and efficacy remain unproven.
FAQ
What is the market cap of Reata Pharmaceuticals (RETA)?
What is Reata Pharmaceuticals, Inc.?
What are Reata's most advanced clinical candidates?
What does NRF2 target?
What diseases are bardoxolone methyl and omaveloxolone being developed to treat?
What recent achievements has Reata Pharmaceuticals made?
Who are Reata's partners?
How is Reata Pharmaceuticals financially sustained?
Why is Reata considered a promising investment?
What is the focus of Reata's research?